The Mitra® VAMS approach represents a significant pillar in new developments related to patient-centric sampling and reduced patient burden. For example, the requirement for uncomfortable venipuncture can be eliminated, making it well suited to both pediatric and neonatal study populations as blood may be collected from a less painful finger or heel stick. Furthermore, convenient at-home sample collection is facilitated by the ease of Mitra® implementation, thereby reducing the need for travel to the clinical site. In preclinical studies, the use of microsampling significantly reduces the requirement for satellite rodents in toxicokinetics (TK) studies and improves the quality of scientific data by eliminating inter-animal variability, since a complete profile is achievable from a single rodent. In order to support our increased client demand for the Mitra® VAMS approach, Altasciences has implemented an innovative sample preparation workflow entitled “Impact-Assisted Extraction”. This process mitigates the remaining bioanalytical hurdles facing the technique, including inconsistent extractability as a function of microsample age and blood HCT bias on drug recovery. Additionally, assay detection limit challenges encountered when sampling low volumes can be met by leveraging the sensitivity and selectivity capabilities of our SCIEX 6500+ TripleQuad with SelexION® technology. Regulated Bioanalysis and Microsampling The experts at Altasciences are continually developing and validating new assays for Mitra® VAMS, with four methods currently validated and six others in various stages of development. In addition, a method validation standard operating procedure (SOP) specific for Mitra® VAMS has been created, which considers the unique parameters requiring assessment to properly support preclinical and/or clinical studies.